Wall Street brokerages predict that DaVita HealthCare Partners Inc. (NYSE:DVA) will announce $3.83 billion in sales for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for DaVita HealthCare Partners’ earnings. The highest sales estimate is $3.92 billion and the lowest is $3.56 billion. DaVita HealthCare Partners posted sales of $3.73 billion in the same quarter last year, which suggests a positive year-over-year growth rate of 2.7%. The firm is scheduled to report its next earnings report on Wednesday, November 1st.
According to Zacks, analysts expect that DaVita HealthCare Partners will report full-year sales of $3.83 billion for the current fiscal year, with estimates ranging from $14.59 billion to $15.43 billion. For the next year, analysts anticipate that the firm will report sales of $15.78 billion per share, with estimates ranging from $14.44 billion to $16.23 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow DaVita HealthCare Partners.
DaVita HealthCare Partners (NYSE:DVA) last issued its quarterly earnings data on Tuesday, August 1st. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.02. DaVita HealthCare Partners had a return on equity of 14.02% and a net margin of 8.68%. The business had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same period in the prior year, the company posted $1.01 EPS. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year.
DVA has been the subject of a number of analyst reports. TheStreet cut shares of DaVita HealthCare Partners from a “b” rating to a “c+” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC set a $70.00 price target on shares of DaVita HealthCare Partners and gave the stock a “buy” rating in a research note on Friday, May 26th. Zacks Investment Research upgraded shares of DaVita HealthCare Partners from a “sell” rating to a “hold” rating in a research note on Thursday, August 3rd. Royal Bank Of Canada restated a “hold” rating and set a $64.00 price target on shares of DaVita HealthCare Partners in a research note on Wednesday, September 6th. Finally, Goldman Sachs Group, Inc. (The) restated a “sell” rating and set a $62.00 price target on shares of DaVita HealthCare Partners in a research note on Thursday, May 25th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $68.88.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://transcriptdaily.com/2017/09/14/3-83-billion-in-sales-expected-for-davita-healthcare-partners-inc-dva-this-quarter.html.
Several hedge funds and other institutional investors have recently bought and sold shares of DVA. SRS Capital Advisors Inc. increased its holdings in shares of DaVita HealthCare Partners by 6.6% during the first quarter. SRS Capital Advisors Inc. now owns 1,966 shares of the company’s stock worth $133,000 after buying an additional 122 shares in the last quarter. Pzena Investment Management LLC increased its holdings in shares of DaVita HealthCare Partners by 2.1% during the second quarter. Pzena Investment Management LLC now owns 3,398 shares of the company’s stock worth $220,000 after buying an additional 71 shares in the last quarter. Pacer Advisors Inc. increased its holdings in shares of DaVita HealthCare Partners by 3.0% during the first quarter. Pacer Advisors Inc. now owns 3,422 shares of the company’s stock worth $233,000 after buying an additional 101 shares in the last quarter. LMR Partners LLP acquired a new stake in shares of DaVita HealthCare Partners during the first quarter worth approximately $242,000. Finally, Elk Creek Partners LLC increased its holdings in shares of DaVita HealthCare Partners by 13.5% during the first quarter. Elk Creek Partners LLC now owns 3,885 shares of the company’s stock worth $264,000 after buying an additional 463 shares in the last quarter. 83.43% of the stock is owned by institutional investors.
DaVita HealthCare Partners (DVA) opened at 59.78 on Thursday. The company has a market capitalization of $11.43 billion, a price-to-earnings ratio of 9.11 and a beta of 0.91. DaVita HealthCare Partners has a one year low of $54.50 and a one year high of $70.16. The company has a 50-day moving average price of $58.69 and a 200-day moving average price of $64.46.
DaVita HealthCare Partners Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.